GLP-1 Heart Health Benefits 2026: SELECT Trial Results & Cardiovascular Protection

The SELECT Trial: What It Found and Why It Matters

The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial is the most important clinical trial in obesity medicine in decades. It enrolled 17,604 adults with overweight or obesity — defined as BMI 27 or higher — and established cardiovascular disease, but without type 2 diabetes. Participants were randomized to semaglutide 2.4 mg once weekly (escalated over 16 weeks) or placebo, and followed for a median of approximately 33 months (maximum 58 months).

The primary endpoint was time to first major adverse cardiovascular event (MACE): a three-point composite of cardiovascular death, nonfatal myocardial infarction (heart attack), or nonfatal stroke. This is the standard primary endpoint used across cardiovascular outcomes trials for drugs in the diabetes and cardiometabolic space, allowing comparison with the extensive cardiovascular outcomes data from GLP-1 and SGLT-2 inhibitor programs.

The 20% reduction in MACE represents a clinically and statistically robust finding. To put it in context: the landmark HOPE trial, which established ramipril as a cornerstone cardiovascular risk reduction therapy, produced a 22% reduction in MACE in a comparable high-risk population. SELECT positions semaglutide as a cardiovascular risk reduction tool of similar magnitude to established cardiometabolic medications — a historic development for a drug that is also the most effective weight loss medication ever studied.

The SELECT result led the FDA to approve a cardiovascular risk reduction indication for semaglutide 2.4 mg (Wegovy) in 2024 — the first weight loss medication to receive such an approval. This regulatory milestone signaled that semaglutide has transitioned from a weight management drug that happens to affect cardiovascular risk to a cardiovascular medication that also produces weight loss. For patients with pre-existing cardiovascular disease and obesity, this dual benefit profile makes semaglutide one of the most compelling medications in modern cardiometabolic medicine. For a broader discussion of GLP-1 access options, see our best GLP-1 provider guide.

Beyond Weight Loss: Direct Cardioprotective Mechanisms

One of the most scientifically significant findings from SELECT analysis was that semaglutide's cardiovascular benefits appear to extend beyond what weight loss alone would predict. Several lines of evidence support this conclusion.

First, the timing of the cardiovascular benefit is instructive. In the Kaplan-Meier curves from SELECT, the event rate curves between semaglutide and placebo begin diverging within the first few months of the trial — before maximal weight loss is achieved. Weight loss is a gradual process that produces its peak cardiovascular effects over months to years; the early separation of event curves suggests that semaglutide is producing cardiovascular benefits through mechanisms that act faster than weight loss can explain.

Second, formal mediation analyses from the SELECT trial estimated that only a portion of the cardiovascular benefit was attributable to weight loss, with the remainder attributable to other effects including blood pressure reduction, lipid changes, glycemic improvements, and direct vascular effects. Semaglutide produces systolic blood pressure reductions of approximately 3 to 5 mmHg — meaningful when considered at a population level over years. It also produces LDL cholesterol reductions, triglyceride reductions, and improvements in HDL function that contribute to atherosclerotic plaque stabilization.

Third, GLP-1 receptors are expressed in cardiac myocytes, vascular smooth muscle cells, endothelial cells, and macrophages within atherosclerotic plaques. Activation of these receptors produces direct anti-inflammatory effects in vascular tissue, reduces foam cell formation (a key step in atherosclerosis progression), and may promote endothelial function. These vascular effects of GLP-1 agonism appear to slow the progression of underlying atherosclerotic disease independently of the metabolic improvements produced by weight loss.

The anti-inflammatory mechanism is particularly compelling. Atherosclerosis is fundamentally an inflammatory disease, and semaglutide's substantial CRP reduction (approximately 37% in SELECT) directly addresses the inflammatory component of cardiovascular risk. For patients with elevated CRP reflecting high-risk atherosclerosis, this anti-inflammatory effect may represent a significant mechanism of cardiovascular protection. See our analysis of CRP reduction on GLP-1 medications for detailed data.

Heart Failure with Preserved Ejection Fraction: STEP-HFpEF Data

Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure characterized by impaired cardiac filling rather than reduced pumping function. It is strongly associated with obesity, accounting for more than half of all heart failure cases in obese patients. HFpEF has historically been one of the most treatment-resistant conditions in cardiology — unlike heart failure with reduced ejection fraction (HFrEF), most standard heart failure therapies showed no benefit in HFpEF until recently.

The STEP-HFpEF trial and its sister trial STEP-HFpEF-DM (enrolling patients with type 2 diabetes) represent a landmark advance in this previously treatment-resistant population. STEP-HFpEF enrolled 529 patients with HFpEF and a BMI of 30 or higher and randomized them to semaglutide 2.4 mg or placebo for 52 weeks.

At 52 weeks, semaglutide produced significant improvements across multiple clinically meaningful endpoints: the Kansas City Cardiomyopathy Questionnaire (KCCQ) score improved by 7.8 points more in the semaglutide group than placebo — well above the clinically meaningful threshold of 5 points. Six-minute walk distance improved by 20.3 meters more in the semaglutide group. CRP, a marker of cardiac inflammation and HFpEF severity, decreased by 43% more in the semaglutide group. Body weight fell by an average of 13.3% in the semaglutide group versus 2.6% in placebo.

Critically, mediation analysis suggested that approximately two-thirds of the symptom benefit was attributable to weight loss and one-third to weight-loss-independent effects — again confirming that semaglutide's cardiac benefits are only partially explained by body weight changes. For patients with HFpEF and obesity who have had limited success with other interventions, semaglutide represents a meaningful new therapeutic option.

Blood Pressure, Lipids, and the Full Cardiometabolic Profile

The cardiovascular benefits of GLP-1 medications extend across the entire cardiometabolic risk factor profile — not just through the headline MACE endpoint. Understanding the breadth of these effects helps clarify why semaglutide produces such a clinically meaningful cardiovascular outcome in high-risk patients.

Blood pressure effects are consistent across the STEP program and SELECT. Semaglutide produces average systolic blood pressure reductions of 3 to 5 mmHg and diastolic reductions of 1 to 2 mmHg. While these are modest by antihypertensive standards, they are additive to other cardiovascular risk reduction effects and occur even in patients who are already on antihypertensive therapy. Patients using GLP-1 therapy alongside existing antihypertensives should have blood pressure monitored to avoid excessive reduction, and medication adjustments may be needed as weight falls.

Lipid effects are also favorable, though more variable. Semaglutide consistently reduces triglycerides by 15 to 25% and produces modest LDL reductions. HDL cholesterol tends to improve in parallel with weight loss. The combination of triglyceride reduction and LDL reduction is particularly relevant to the residual cardiovascular risk that persists in patients on statin therapy — a population that makes up the majority of patients with established cardiovascular disease.

The glycemic effects of semaglutide in non-diabetic patients — which include the 73% reduction in new-onset diabetes seen in SELECT — represent an additional cardiovascular benefit pathway, since diabetes itself is a major cardiovascular risk factor. The convergence of weight loss, blood pressure reduction, lipid improvement, anti-inflammatory effects, and glycemic protection makes semaglutide one of the most comprehensive cardiometabolic interventions available. For the complete discussion of semaglutide's diabetes prevention data, see our prediabetes prevention guide.

Clinical Implications: Who Benefits Most in 2026

The SELECT trial enrolled patients with established cardiovascular disease — meaning prior heart attack, prior stroke, or peripheral arterial disease. These patients represent the highest-risk population for recurrent cardiovascular events and therefore derive the largest absolute benefit from risk reduction. For this population, the SELECT data strongly supports semaglutide as a disease-modifying cardiovascular therapy, not simply a weight management adjunct.

Patients with multiple cardiovascular risk factors but no established event (primary prevention patients) were not studied in SELECT. However, many cardiologists and obesity medicine specialists view the SELECT findings as supportive of GLP-1 use in high-risk primary prevention patients, particularly those with metabolic syndrome, hypertension, dyslipidemia, and prediabetes. The 2024 ACC/AHA obesity and cardiovascular disease guidelines explicitly incorporate GLP-1 medications as cardiovascular risk reduction tools for patients with overweight or obesity.

For patients wondering whether they qualify for semaglutide based on cardiovascular history, the eligibility criteria include BMI ≥ 27 with established cardiovascular disease (prior MI, stroke, or peripheral arterial disease) — criteria that an enormous proportion of patients with cardiovascular disease and overweight meet. Trimi's clinical intake evaluates cardiovascular history as part of the baseline assessment, allowing providers to appropriately counsel patients on cardiovascular as well as weight loss benefits. To compare GLP-1 access options, review our best online weight loss clinics 2026 guide. Patients also interested in understanding what clinical monitoring is appropriate should review our guide on monitoring labs while on GLP-1 therapy.

The SELECT data also has important implications for patients who are on GLP-1 therapy primarily for weight loss without known cardiovascular disease: the cardiovascular benefits provide additional medical justification for treatment beyond cosmetic or functional goals. Understanding that weight loss medication produces heart disease protection at the level of established cardiovascular drugs changes the risk-benefit calculus for many patients and providers who might otherwise view GLP-1 therapy as optional rather than medically indicated. For patients comparing semaglutide to tirzepatide in the cardiovascular context, see our comprehensive comparison article which discusses current cardiovascular data for both medications.

Frequently Asked Questions